Journal of Vaccine Research 2024, Vol.14, No.2, 65-75 http://medscipublisher.com/index.php/jvr 73 Du J.J., Wang C.W., Xu W.B., Zhang L., Tang Y.K., Zhou S.H., Gao X., Yang G., and Guo J., 2020, Multifunctional protein conjugates with built-in adjuvant (adjuvant-protein-antigen) as cancer vaccines boost potent immune responses, Iscience, 23(3). https://doi.org/10.1016/j.isci.2020.100935 PMid:32146328 PMCid:PMC7063246 Godi A., Panwar K., Haque M., Cocuzza C.E., Andrews N., Southern J., Turner P., Miller E., and Beddows S., 2019, Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine, Vaccine, 37(18): 2455-2462. https://doi.org/10.1016/j.vaccine.2019.03.052 PMid:30926298 Gonzalez-Lopez A., Oostendorp J., Koernicke T., Fadini T., D'Oro U., Baker S., O'hagan D., Giudice G., Siena E., Finco O., and Medini D., 2019, Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): a phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine, Clinical Immunology, 209: 108275. https://doi.org/10.1016/j.clim.2019.108275 PMid:31669193 Gouttefangeas C., and Rammensee H.G., 2018, Personalized cancer vaccines: adjuvants are important, too, Cancer Immunology, Immunotherapy, 67(12): 1911-1918. https://doi.org/10.1007/s00262-018-2158-4 PMid:29644387 PMCid:PMC11028305 Ho N.I., Huis in't Veld L.G., Raaijmakers T.K., and Adema G.J., 2018, Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines?, Frontiers in Immunology, 9: 2874. https://doi.org/10.3389/fimmu.2018.02874 PMid:30619259 PMCid:PMC6300500 Hu H.G., and Li Y.M., 2020, Emerging adjuvants for cancer immunotherapy, Frontiers in Chemistry, 8: 601. https://doi.org/10.3389/fchem.2020.00601 PMid:32850636 PMCid:PMC7406886 Kim H., Niu L., Larson P., Kucaba T.A., Murphy K.A., James B.R., Ferguson D., Griffith T., and Panyam J., 2018, Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy, Biomaterials, 164: 38-53. https://doi.org/10.1016/j.biomaterials.2018.02.034 PMid:29482062 Kocabaş B.B., Almacioglu K., Bulut E.A., Gucluler G., Tincer G., Bayik D., Gursel M., and Gursel I., 2020, Dual-adjuvant effect of pH-sensitive liposomes loaded with STING and TLR9 agonists regress tumor development by enhancing Th1 immune response, Journal of Controlled Release, 328: 587-595. https://doi.org/10.1016/j.jconrel.2020.09.040 PMid:32971199 Lee W., and Suresh M., 2022, Vaccine adjuvants to engage the cross-presentation pathway, Frontiers in Immunology, 13: 940047. https://doi.org/10.3389/fimmu.2022.940047 PMid:35979365 PMCid:PMC9376467 Lehtinen M., Apter D., Eriksson T., Harjula K., Hokkanen M., Lehtinen T., Natunen K., Damaso S., Soila M., Bi D., and Struyf F., 2020, Effectiveness of the AS04‐adjuvanted HPV‐16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community‐randomized trial, International Journal of Cancer, 147(1): 170-174. https://doi.org/10.1002/ijc.32791 PMid:31736068 PMCid:PMC7318585 Li W.H., Su J.Y., and Li Y.M., 2022, Rational design of T-cell-and B-cell-based therapeutic cancer vaccines, Accounts of Chemical Research, 55(18): 2660-2671. https://doi.org/10.1021/acs.accounts.2c00360 PMid:36048514 Li X., Wang X., and Ito A., 2018, Tailoring inorganic nanoadjuvants towards next-generation vaccines, Chemical Society Reviews, 47(13): 4954-4980. https://doi.org/10.1039/C8CS00028J PMid:29911725 Liu Q., Zhou Y., Li M., Zhao L., Ren J., Li D., Tan Z., Wang K., Li H., Hussain M., Zhang L., Shen G., Zhu J., and Tao J., 2019, Polyethylenimine hybrid thin-shell hollow mesoporous silica nanoparticles as vaccine self-adjuvants for cancer immunotherapy, ACS Applied Materials and Interfaces, 11(51): 47798-47809. https://doi.org/10.1021/acsami.9b19446 PMid:31773941 Liu Y., Wang Z., Yu F., Li M., Zhu H., Wang K., Meng M., and Zhao W., 2021, The adjuvant of α-galactosylceramide presented by gold nanoparticles enhances antitumor immune responses of MUC1 antigen-based tumor vaccines, International Journal of Nanomedicine, 403-420. https://doi.org/10.2147/IJN.S273883 PMid:33469292 PMCid:PMC7813472
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==